tbuckley/cabot-search huggingface dataset:
PATH-58. REAPPRAISAL OF HISTOLOGICAL FEATURES AND MOLECULAR ANALYSIS OF LOWER GRADE GLIOMAS AND ASSOCIATION WITH OVERALL SURVIVALS
Authors: Eriel Pareira, Kentaro Ohara, Makoto Shibuya, Yu Nakagawa, Kazunari Yoshida, Hikaru Sasaki
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Based on WHO 2016 classification of grade II and III glioma (lower grade glioma/LrGG), the pathological diagnosis of oligodendroglioma is associated with IDH mutation status and 1p/19q codeletion. It was reported that the classical oligodendroglioma features closely related to the presence of 1p/19q codeletion. In this study, we compared histology of oligodendroglial features with molecular prognostic factors such as ATRX, TERT, IDH1/2 and copy number aberrations and their relations with patients’ prognoses. METHODS In this study, we analyzed 94 cases of primary LrGG resected in 1990 to 2016 in Keio University Hospital, Japan. Using WHO 2007 classification of LrGG, we re-diagnosed the tumors based on their histological features and compared them to their initial diagnoses (made by the pathologists on the time of resections). The presence of classic for oligodendroglioma (CFO) features were closely documented. ATRX mutation was analyzed by immunohistochemistry. IDH1/2 and TERT mutation status were analyzed using Sanger sequence. Copy number aberrations analyzed using comparative genomic hybridization (CGH). In addition, we analyzed IDH-mut/codeleted tumors with cancer genetic panel. RESULTS Re-diagnosis shown there is a shift of trend toward oligodendroglioma diagnoses from astrocytoma and a trend of change from grade II to grade III. IDH-mut/codel tumors shown no correlation between CFO and molecular prognostic factors nor CNAs but there was correlation between overall survival and molecular factors such as CIC (p= 0.046) and FUBP1(p= 0.03). IDH-mut/non-codel tumors shown no correlation between CFO and overall survival but ATRX and gain of 8q were found to be correlated with pathological diagnosis. CONCLUSION There is a lot of change in histological diagnosis of oligodendroglioma from each eras. IDH-mut/codel tumors shown there is correlation between FUBP1 and CIC with overall survivals. IDH-mut/noncodel tumors shown there is correlation between gain of 8q with overall survivals.
PATH-66. THE GENOMIC LANDSCAPE OF SPINAL CORD EPENDYMOMA
Authors: Biswarathan Ramani, Javier Villanueva-Meyer, Christine Glastonbury, Ece Meram, Kyle Walsh, Jennie Taylor, Jessica van Ziffle, Courtney Onodera, James Grenert, Andrew Bollen, Arie Perry, Tarik Tihan, David Solomon, Melike Pekmezci
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Ependymomas are seen throughout the neural axis but spinal cord is most common in adults. A subset arises in the setting of neurofibromatosis 2, whereas most are sporadic, potentially with somatic NF2 inactivation. The genetic drivers in NF2 wildtype tumors are unknown, as is the spectrum of cooperating genetic alterations. METHODS We performed targeted next-generation sequencing (NGS) to assess mutations, rearrangements, and chromosomal copy number alterations in 46 adult spinal cord ependymomas. RESULTS The 24 females and 22 males ranged from 20–73 (median 46) years of age. Tumors were in the cervical (n=24), thoracic (n=12), and lumbar (n=10) spinal cord. Nine tumors (20%) harbored truncating NF2 mutations with loss of the remaining wildtype allele, with frequent monosomy 13q. Thirteen NF2-wildtype tumors (28%) showed monosomy 22q with frequent monosomy 13q and trisomy 7, 9, and 12. Seventeen tumors (37%) carried a near-tetraploid genome, likely due to genomic reduplication with frequent preservation of diploidy in chromosomes 13q (77%), 14q (88%), 21q (53%) and 22q (65%). Remaining cases did not show a recurrent pattern, but one harbored focal high-level MYCN amplification. Three of the six recurrences were seen in the last subgroup; however, there was no significant difference for progression-free survival between four subgroups. None of the NF2-mutant tumors were in lumbar spinal cord, but there was no difference for tumor location or patient age between four subgroups. DISCUSSION Biallelic NF2 mutational inactivation characterizes only a subset of spinal cord ependymomas, and MYCN amplification is likely a genetic driver in a small subset of NF2 wildtype cases. The high frequency of chromosome 22q loss even in NF2-wildtype tumors raises the possibility of cryptic alterations in the NF2 gene not detected by our panel, or perhaps implicates the presence of another as yet unidentified tumor suppressor gene on chromosome 22q.
On the Redox Profile of B- Cell Terminal Differentiation and Multiple Myeloma: New Insights and Therapeutic Opportunities
Authors: Wafa Hassen, Alboukadel Kassambara, Michel Jourdan, Stephanie Boireau, Anja Seckinger, Dirk Hose, Yubin Kang, Bernard Klein, Jerome Moreaux
Journal: Blood (2016)
Intraclonal Heterogeneity Caused By Activation-Induced Cytidine Deaminase Is Not a Prognostic Biomarker in Untreated Advanced Stage Follicular Lymphoma: An Analysis of SWOG S0016
Authors: Richard Burack, Hongli Li, Diana G Adlowitz, Janice M Spence, Michael L. Leblanc, Lisa M. Rimsza, Rita M. Braziel, Catherine M. Spier, Mark S Kaminski, John P. Leonard, Richard I. Fisher, Sonali M. Smith, Jonathan W. Friedberg
Journal: Blood (2019)
Phase I/II trial of preoperative oxaliplatin, docetaxel, capecitabine, and radiation for localized esophageal cancer
Authors: A. A. Meluch, D. R. Spigel, F. A. Greco, D. A. Yardley, H. A. Burris, C. Farley, J. D. Peyton, D. L. Shipley, R. G. Steis, J. D. Hainsworth
Journal: Journal of Clinical Oncology (2007)

4595 Background: Preoperative chemoradiotherapy is a primary treatment option for patients (pts) with resectable esophageal cancer. Combination regimens using newer agents may improve pt outcomes. This multicenter community-based trial examined a modern triplet regimen comprised of oxaliplatin (O), docetaxel (D), and capecitabine (C) combined with radiation (RT). Methods: The primary endpoints were objective response rate (ORR) and safety. Eligibility criteria: pts with resectable stage I-III cancer of the mid-/distal-esophagus or gastroesophageal junction, measurable disease, ECOG PS 0–1, and informed consent. Treatment: O 40 mg/m 2 IV and D 20 mg/m 2 IV weekly x 5; C 1,000 mg/m 2 PO twice daily D1–7, 15–21, 29–35; and concurrent RT to 45 Gy. Pts were resected 4–8 weeks later. O/D/RT safety was determined in a phase I portion (n=10) before adding C in a phase II portion. Results: 43 pts were enrolled from 9/04 to 12/06 (trial ongoing, n=60 planned). Data on 38 pts are available for analysis. Baseline characteristics: median age 61 years; male/female, 76%/24%; ECOG PS 0/1, 32%/68%; adenocarcinoma/squamous, 74%/26%; and stage I, II, III, 8%/45%/47%. The ORR was 58% (95% CI 42%-72%), with 4 complete and 18 partial responses. 37% had stable disease, and 1 pt had progressive disease (PD). 26 pts (68%) were resected. Unresected pts: awaiting surgery, 3 pts; poor PS, 4 pts; PD, 1 pt; pt choice, 1 pt; death, 3 pts. Pathologic complete responses were seen in 17 pts (65%). With a median follow-up of 16 months, 1-year progression-free survival (PFS) and overall survival (OS) are 58% and 64%, respectively. Median PFS and OS have not been reached. Grade (G) 3/4 non-hematologic toxicity: anorexia (21%), dehydration, esophagitis (16% each), nausea (13%), and dysphagia, fatigue, vomiting, and pain (11% each). Other G3/4 non- hematologic toxicities were = 5%. No G3/4 hematologic toxicities or treatment-related deaths occurred. Conclusions: O/D/C/RT appears safe and active as a preoperative regimen for resectable esophageal cancer - with a G3/4 esophagitis rate that compares favorably with historical combination regimens. Additional accrual and follow-up are needed to determine if these benefits are sustained. No significant financial relationships to disclose.
Characterization of longitudinal wheeze phenotypes from infancy to adolescence in Project Viva, a prebirth cohort study
Authors: Joanne E. Sordillo, Brent A. Coull, Sheryl L. Rifas-Shiman, Ann Chen Wu, Sharon M. Lutz, Marie-France Hivert, Emily Oken, Diane R. Gold
Journal: Journal of Allergy and Clinical Immunology (2019)
Minimally invasive surgery alone compared with intensity-modulated radiotherapy for primary stage I nasopharyngeal carcinoma
Authors: You-Ping Liu, Xing Lv, Xiong Zou, Yi-Jun Hua, Rui You, Qi Yang, Le Xia, Shao-Yan Guo, Wen Hu, Meng-Xia Zhang, Si-Yuan Chen, Mei Lin, Yu-Long Xie, Li-Zhi Liu, Rui Sun, Pei-Yu Huang, Wei Fan, Xiang Guo, Ming-Huang Hong, Ming-Yuan Chen
Journal: Cancer Communications (2019)

The National Comprehensive Cancer Network guidelines recommend intensity-modulated radiotherapy (IMRT) as the primary curative treatment for newly diagnosed nasopharyngeal carcinoma (NPC), but the radiation-related complications and relatively high medical costs remain a consequential burden for the patients. Endoscopic nasopharyngectomy (ENPG) was successfully applied in recurrent NPC with radiation free and relatively low medical costs. In this study, we examined whether ENPG could be an effective treatment for localized stage I NPC. Ten newly diagnosed localized stage I NPC patients voluntarily received ENPG alone from June 2007 to September 2017 in Sun Yat-sen University Cancer Center. Simultaneously, the data of 329 stage I NPC patients treated with IMRT were collected and used as a reference cohort. The survival outcomes, quality of life (QOL), and medical costs between two groups were compared. After a median follow-up of 59.0 months (95% CI 53.4–64.6), no death, locoregional recurrence, or distant metastasis was observed in the 10 patients treated with ENPG. The 5-year overall survival, local relapse-free survival, regional relapse-free survival, and distant metastasis-free survival among the ENPG-treated patients was similar to that among the IMRT-treated patients (100% vs. 99.1%, 100% vs. 97.7%, 100% vs. 99.0%, 100% vs. 97.4%, respectively, P > 0.05). In addition, compared with IMRT, ENPG was associated with decreased total medical costs ($ 4090.42 ± 1502.65 vs. $ 12620.88 ± 4242.65, P < 0.001) and improved QOL scores including dry mouth (3.3 ± 10.5 vs. 34.4 ± 25.8, P < 0.001) and sticky saliva (3.3 ± 10.5 vs. 32.6 ± 23.3, P < 0.001). ENPG alone was associated with promising long-term survival outcomes, low medical costs, and satisfactory QOL and might therefore be an alternative strategy for treating newly diagnosed localized stage I NPC patients who refused radiotherapy. However, the application of ENPG should be prudent, and prospective clinical trials were needed to further verify the results.
Haploidentical Hematopoietic Stem Cell Transplantation May Improve Prognosis in Non-Infant Children with t(v;11q23)/MLL-Rearranged B-Acute Lymphoblastic Leukemia
Authors: Lu Bai, Yi-Fei Cheng, Ai-Dong Lu, Pan Suo, Yu Wang, Ying-Xi Zuo, Chen-Hua Yan, Jun Wu, Yue-Ping Jia, Yu-Qian Sun, Yu-Hong Chen, Huan Chen, Kai-yan Liu, Wei Han, Lan-Ping Xu, Jing-Bo Wang, Xiang-Feng Tang, Hui-Ren Chen, Le-Ping Zhang, Xiao-Jun Huang
Journal: Blood (2019)
Management of Neutropenia during Venetoclax-Based Combination Treatment in Patients with Newly Diagnosed Acute Myeloid Leukemia
Authors: Keith W. Pratz, Andrew H. Wei, Daniel A Pollyea, Brian A Jonas, Walter Fiedler, Christian Recher, Wan-Jen Hong, Jalaja Potluri, Catherine Miller, Gail J. Roboz
Journal: Blood (2019)
PATH-39. DNA MISMATCH REPAIR ENZYME IMMUNOHISTOCHEMISTRY IS A RAPID, EFFECTIVE SCREENING TEST FOR HYPERMUTATED GLIOMAS
Authors: Matthew McCord, Alicia Steffens, Kwok-Ling Kam, Rodrigo Javier, Kathleen McCortney, Craig Horbinski
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND While gliomas with hypermutated DNA are resistant to alkylating agents like temozolomide, they may be especially responsive to immunotherapy, since they express abundant neoantigens on their cell surfaces. Screening for hypermutated gliomas is currently being done through next-generation sequencing (NGS) panels that cover large portions of tumor DNA, although this is costly and access to such testing is not universal. Since hypermutated gliomas typically contain inactivating mutations in one of the main DNA mismatch repair (MMR) proteins, and cancers with an MMR mutation usually show loss of normal MMR protein, we sought to determine the feasibility of rapidly screening for hypermutated gliomas with an MMR immunohistochemistry (IHC) panel that is already in widespread use for colorectal adenocarcinomas. METHODS Tumor mutation burden (TMB) was determined via NGS for 101 gliomas, including 64 GBMs, 24 grade II-III astrocytomas, 9 grade II-III oligodendrogliomas, and 4 grade I gliomas. IHC for MSH2, MSH6, MLH1, and PMS2 was performed and analyzed on all gliomas while blinded to mutation profile and TMB. RESULTS Seven of 101 gliomas (7%) showed loss of an MMR protein by IHC. All 7 had matching MMR gene mutations and were hypermutated (100%), defined as TMB &gt;20 per megabase of DNA. Of the remaining 94 with intact MMR IHC, only one was hypermutated. That case had an inactivating splice region mutation in another gene involved in DNA repair, ATM, although ATM is not part of the IHC panel originally developed for colorectal cancer. Overall sensitivity and specificity of the current MMR IHC panel for hypermutated gliomas was therefore 88% and 100%, respectively. CONCLUSION The colorectal MMR IHC panel, available in virtually all clinical IHC labs, is also a good screening test for hypermutated gliomas. Expansion of the panel to include even more DNA repair proteins, like ATM, would enhance its utility.
Analysis of Outcomes of Younger (≤ 55 Years) Compared with Older (&gt; 55 Years) Patients with Chronic Lymphocytic Leukaemia (CLL) in Seven Studies Conducted By the German CLL Study Group (GCLLSG)
Authors: Nisha De Silva, Sandra Robrecht, Can Zhang, Paula Cramer, Anna- Maria Fink, Kirsten Fischer, Valentin Goede, Carmen D. Herling, Manuela Hoechstetter, Clemens-Martin Wendtner, Michael Hallek, Barbara F. Eichhorst
Journal: Blood (2019)
In inpatients with community-acquired pneumonia, a bundled intervention with steroids did not reduce length of stay
Authors: Alice Gallo de Moraes, John C. O’Horo
Journal: Annals of Internal Medicine (2019)

Source Citation Lloyd M, Karahalios A, Janus E, et al; Improving Evidence-Based Treatment Gaps and Outcomes in Community-Acquired Pneumonia (IMPROVE-GAP) Implementation Team at Western Health. Effectiveness of a bundled intervention including adjunctive corticosteroids on outcomes of hospitalized patients with community-acquired pneumonia: a stepped-wedge randomized clinical trial. JAMA Intern Med. 2019;1791052-60. [Epub ahead of print]. 31282921
A Phase I/II Study of Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: PrE0404
Authors: Jonathon B. Cohen, Craig A. Portell, Mehdi Hamadani, Opeyemi Jegede, Catherine Diefenbach, Kevin A. David, Christopher D. Fletcher, Daniel J. Landsburg, Brad S. Kahl
Journal: Blood (2019)
Effect of Combination l-Citrulline and Metformin Treatment on Motor Function in Patients With Duchenne Muscular Dystrophy
Authors: P Hafner, U Bonati, A Klein, D Rubino, V Gocheva, S Schmidt, J Schroeder, G Bernert, V Laugel, M Steinlin, A Capone, M Gloor, O Bieri, L G Hemkens, B Speich, T Zumbrunn, N Gueven, D Fischer
Journal: JAMA Network Open (2019)
Elispots and Ex Vivo Expansion of FVIII-Specific T-Cell Clones Confirm Specificity of CD4+ T-Cell Responses to Self-FVIII in Healthy Non-Hemophilic Blood Donors
Authors: Ahmad Faisal Karim, Pooja Vir, Devi Gunasekera, Allen I. Stering, Kenneth Lieuw, Kathleen P. Pratt
Journal: Blood (2019)
Ixazomib, Rituximab and Dexamethasone (IRD) in Patients with Relapsed or Progressive Waldenstrom's Macroblobulinemia: Results of the Prospective Phase I/II HOVON 124/Ecwm-R2 Trial
Authors: Marie José Kersten, Monique C. Minnema, Josephine M. Vos, Kazem Nasserinejad, Marcel Kap, Eftathios Kastritis, Maria Gavriatopoulou, Martine E.D. Chamuleau, Dries Deeren, Lidwine Winnifred Tick, Jeanette K. Doorduijn, Fritz Offner, Lara H Bohmer, Karima Amaador, Roberto D Liu, Steven T Pals, Meletios A. Dimopoulos
Journal: Blood (2019)
Bornholm Disease in Children
Authors: H. W. Bland, G. T. Newton
Journal: BMJ (1947)

Apparent intracellular free Ca++ concentration [(Ca++]i) was measured in differentiated N1E-115 neuroblastoma by microinjecting cells with aequorin (estimated intracellular concentration, 4 microM) and measuring light emission. Histamine produced a transient, dose-dependent increase in [Ca++]i. Pyrilamine blocked completely the response to histamine whereas cimetidine had no effect. Omitting Ca++ from the external medium reversibly blocked the response. As well as a rise in [Ca++]i, histamine caused a concomitant cell hyperpolarization that was not blocked by ouabain, low Cl-, tetraethylammonium chloride/tetradotoxin or metiamide but was blocked by apamin and pyrilamine. A secondary small depolarization caused by histamine was also blocked by apamin but not by ouabain, low Cl- or tetraethylammonium chloride/tetrodotoxin. Direct iontophoretic injection of Ca++ into cells caused only hyperpolarization. Injection of inositol 1,4,5-trisphosphate [IP3(1,4,5)] caused an increase in [Ca++]i and rapid hyperpolarization. Inositol 1,3,4-trisphosphate [IP3(1,3,4)] caused an increase in [Ca++]i, rapid hyperpolarization and a slower depolarization. Repeated injections of IP3(1,3,4) led to a diminished [Ca++]i response and decreased hyperpolarization but had no effect on depolarization. Inositol 1,3,4,5-tetrakisphosphate was without effect on [Ca++]i or on cellular membrane potential. The results suggest that histamine causes an H1 receptor-dependent increase in [Ca++]i, probably by the increased entry of extracellular Ca++, although there may be a contribution from intracellular Ca++ released by IP3(1,4,5). The increase in [Ca++]i activates K+ channels leading to cell hyperpolarization. IP3(1,3,4) formed from inositol 1,3,4,5-tetrakisphosphate, which is itself a product of IP3(1,4,5), causes a slower depolarization by a mechanism that does not involve Na+ channels or an increase in [Ca++]i.
C-type lectin receptors Mcl and Mincle control development of multiple sclerosis–like neuroinflammation
Authors: Marie N’diaye, Susanna Brauner, Sevasti Flytzani, Lara Kular, Andreas Warnecke, Milena Z. Adzemovic, Eliane Piket, Jin-Hong Min, Will Edwards, Filia Mela, Hoi Ying Choi, Vera Magg, Tojo James, Magdalena Linden, Holger M. Reichardt, Michael R. Daws, Jack van Horssen, Ingrid Kockum, Robert A. Harris, Tomas Olsson, Andre O. Guerreiro-Cacais, Maja Jagodic
Journal: Journal of Clinical Investigation (2019)

Pattern recognition receptors (PRRs) are crucial for responses to infections and tissue damage; however, their role in autoimmunity is less clear. Herein we demonstrate that 2 C-type lectin receptors (CLRs) Mcl and Mincle play an important role in the pathogenesis of experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS). Congenic rats expressing lower levels of Mcl and Mincle on myeloid cells exhibited a drastic reduction in EAE incidence. In vivo silencing of Mcl and Mincle or blockade of their endogenous ligand SAP130 revealed that these receptors' expression in the central nervous system is crucial for T cell recruitment and reactivation into a pathogenic Th17/GM-CSF phenotype. Consistent with this, we uncovered MCL- and MINCLE-expressing cells in brain lesions of MS patients and we further found an upregulation of the MCL/MINCLE signaling pathway and an increased response following MCL/MINCLE stimulation in peripheral blood mononuclear cells from MS patients. Together, these data support a role for CLRs in autoimmunity and implicate the MCL/MINCLE pathway as a potential therapeutic target in MS.
Impact of Iron Overload and Iron Removal Therapy on Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in the Patients with Severe Aplastic Anemia
Authors: Tianzhong Pan, Baolin Tang, Xiaoyu Zhu, Huilan Liu, Kaidi Song, Xiang Wan, Wen Yao, Zimin Sun
Journal: Blood (2019)
Re-Induction and Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [Iomab-B] Leads to High Rates of Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial
Authors: Boglarka Gyurkocza, Rajneesh Nath, Patrick J. Stiff, Edward Agura, Mark Litzow, Ben Tomlinson, Hannah K. Choe, Sunil Abhyankar, Stuart Seropian, George L. Chen, Parameswaran Hari, Zaid S. Al-Kadhimi, James M. Foran, Johnnie Orozco, Koen Van Besien, Mitchell Sabloff, Partow Kebriaei, Moshe Yair Levy, Hillard M Lazarus, Sergio A Giralt, Mark S. Berger, Vijay Reddy, John M. Pagel
Journal: Blood (2019)
Superiority of Epstein-Barr Virus (EBV) DNA in the Plasma over Whole Blood in Prognostication of Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL)
Authors: Joo Young Ha, Heungsup Sung, Ah Ra Jung, Yoon Sei Lee, Sang-wook Lee, Jin-Sook Ryu, Eun Jin Chae, Kyoung Won Kim, Jooryung Huh, Chan-Sik Park, Dong-Joon Kim, Seon-Ok Kim, Cheolwon Suh, Dok Hyun Yoon
Journal: Blood (2019)
BRAF inhibitor treatment in classic hairy cell leukemia: a long-term follow-up study of patients treated outside clinical trials
Authors: Nora Liebers, Tobias Roider, Jan-Paul Bohn, Isabella Haberbosch, Andreas Pircher, Barbara Ferstl, Monika Ebnöther, Clemens-Martin Wendtner, Claire Dearden, George A. Follows, Anthony D. Ho, Carsten Müller-Tidow, Peter Dreger, Xavier Troussard, Thorsten Zenz, Sascha Dietrich
Journal: Leukemia (2019)
Complications of Arterial Puncture
Authors: S. Ray
Journal: BMJ (1964)

others ?Would they really be at ease in a genuinely democratic society of staff and patients ?He advocates privileges for psychiatric consultants similar to those thought to be enjoyed by colleagues in general-hospitals.However, general and teaching hospitals must be surely among the most conservative and hierarchical organizations in our society.It is precisely the virtue of a therapeutic community, to which Dr. Entwistle uncom- prehendingly refers, that it embodies methods of dissolving hierarchy.A democratic group requires leadership.It is convenient for a leader, as the representative of the common will of the community, to hold a symbolic office.The title of medical superintendent for this is as good or bad as any other.What matters is not the title but the way in which it is used.Our experience is the reverse of that to which Dr. Entwistle alludes.Without medical superintendents it is doubtful whether the major developments which have transformed progressive mental hospitals could have been achieved.-Iam, etc.,
Distinct Chromatin Accessibility Changes, Aberrant Transcription Factor Networks Combined with Novel Oncogenic Enhancers Characterise Myeloma-Initiating Genetic Events
Authors: Nikolaos Trasanidis, Jaime Alvarez-Benayas, Alexia Katsarou, Aristeidis Chaidos, Philippa C May, Kanagaraju Ponnusamy, Xiaolin Xiao, Marco Bua, Maria Atta, Irene Roberts, Holger W Auner, Evdoxia Hatjiharissi, Maria Papaioannou, Valentina S Caputo, Ian Sudbery, Anastasios Karadimitris
Journal: Blood (2019)